Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD

Jin Imai,Shinji Takashimizu,Nana Suzuki,Kana Ohshinden,Kana Sawamoto,Yusuke Mishima,Kota Tsuruya,Yoshitaka Arase,Mitsuhiko Yamano,Noriaki Kishimoto,Chizumi Yamada,Nagamu Inoue,Kengo Moriyama,Akiyasu Baba,Hidekazu Suzuki,Tatehiro Kagawa,Yasuhiro Nishizaki
DOI: https://doi.org/10.1038/s41598-024-64301-3
IF: 4.6
2024-06-13
Scientific Reports
Abstract:A novel concept of Metabolic Associated Fatty Liver Disease (MAFLD) was proposed, incorporating metabolic abnormalities such as obesity and diabetes, which are risk factors that affect the prognosis. Non-Alcoholic Fatty Liver Disease (NAFLD), entails fat accumulation in the liver without alcohol consumption and is often linked to obesity, insulin resistance, and metabolic syndrome. However, the broad nature of the disease concept has hindered prognosis accuracy. In this study, we assess the contribution of the impact of diagnostic criteria for MAFLD on metabolic disease progression compared to conventional diagnostic criteria for NAFLD. A total of 7159 patient who were presented to the health screening center in Tokai University Hospital both in 2015 and 2020 were included in the study. Fatty liver was diagnosed using abdominal ultrasonography. The diagnostic criteria for NAFLD were consistent with the global guidelines based on alcohol consumption. The diagnostic criteria for MAFLD were based on the International Consensus Panel. Medications (anti-hypertensive, diabetic, and dyslipidemia medications) were evaluated by self-administration in the submitted medical questionnaire. A total of 2500 (34.9%) participants were diagnosed with fatty liver (FL +), 1811 (72.4%) fit both NAFLD and MAFLD diagnostic criteria (overlap), 230 (9.2%) fit only the NAFLD diagnostic criteria (NAFLD group) and 404 (16.1%) fit the MAFLD diagnostic criteria (MAFLD group) at 2015. Over the next 5 years, medication rates increased in the NAFLD group for anti-hypertensive, + 17 (7.4%); diabetes, + 3 (1.3%); and dyslipidemia, + 32 (13.9%). In contrast, the only-MAFLD group showed a more significant increase with + 49 (12.1%), + 21 (5.2%), and + 49 (12.1%), for the respective medications, indicating a substantial rise in patients starting new medications. Our analysis of repeated health check-ups on participants revealed that the diagnostic criteria for MAFLD are more predictive of future treatment for metabolic disease than conventional diagnostic criteria for NAFLD.
multidisciplinary sciences
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate the effectiveness of the diagnostic criteria for metabolic - associated fatty liver disease (MAFLD) in predicting the progression of metabolic diseases compared with the traditional non - alcoholic fatty liver disease (NAFLD) diagnostic criteria. Specifically, the study aims to evaluate whether the MAFLD diagnostic criteria can better predict the future treatment needs for metabolic diseases than the NAFLD diagnostic criteria by analyzing routine health check - up data and tracking the treatment of patients within 5 years. ### Research Background - **NAFLD**: Non - alcoholic fatty liver disease, which refers to the accumulation of fat in the liver without alcohol consumption and is often associated with obesity, insulin resistance and metabolic syndrome. - **MAFLD**: Metabolic - associated fatty liver disease, a new concept that includes metabolic abnormalities such as obesity and diabetes as risk factors, which affect the prognosis. - **Research Purpose**: To compare the effects of MAFLD and NAFLD diagnostic criteria in predicting the progression of metabolic diseases. ### Research Methods - **Participants**: 7,159 patients who were examined at the Health Screening Center of the University of Tokyo Hospital in 2015 and 2020. - **Diagnostic Criteria**: - **NAFLD**: Diagnose fatty liver by abdominal ultrasound and exclude other causes of hepatic steatosis, such as excessive alcohol consumption. - **MAFLD**: Based on the criteria of the international consensus group, considering metabolic abnormal factors. - **Data Analysis**: Use SPSS 19.0 for statistical analysis, including the calculation of mean and standard deviation, chi - square test and t - test. ### Main Findings - **Patient Distribution**: - 2,500 patients were diagnosed with fatty liver (FL+). - 1,811 patients met both NAFLD and MAFLD diagnostic criteria (overlap group). - 230 patients only met the NAFLD diagnostic criteria (NAFLD group). - 404 patients only met the MAFLD diagnostic criteria (MAFLD group). - **Metabolic Disease Progression**: - Within 5 years, the drug use rates for hypertension, diabetes and hyperlipidemia in the NAFLD group increased by 7.4%, 1.3% and 13.9% respectively. - The corresponding drug use rates in the MAFLD group increased by 12.1%, 5.2% and 12.1% respectively, showing a more significant increase. - **Conclusion**: The MAFLD diagnostic criteria can better predict the future treatment needs for metabolic diseases than the NAFLD diagnostic criteria. ### Discussion - **Metabolic Risk Factors**: MAFLD not only focuses on the fat accumulation in the liver, but also considers metabolic abnormal factors, such as obesity, insulin resistance, type 2 diabetes and hyperlipidemia. - **Clinical Significance**: The MAFLD diagnostic criteria are helpful for more accurately identifying patients with metabolic diseases that need intervention, especially patients with hypertension and diabetes. ### Limitations - **Self - Reported Drug Use**: There may be inaccuracies. - **Lack of Liver Fibrosis Assessment**: No assessment such as elastography was carried out, and the overall liver injury situation could not be fully understood. ### Conclusion This study proves that the MAFLD diagnostic criteria can better predict the future treatment needs for metabolic diseases than the traditional NAFLD diagnostic criteria. This finding is helpful for better management and prevention of metabolic diseases.